

Benedikt Simbrunner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1524300/publications.pdf>

Version: 2024-02-01

62
papers

1,142
citations

361413
20
h-index

454955
30
g-index

62
all docs

62
docs citations

62
times ranked

808
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. <i>Journal of Hepatology</i> , 2021, 74, 819-828.	3.7	96
2	Gut-liver axis signaling in portal hypertension. <i>World Journal of Gastroenterology</i> , 2019, 25, 5897-5917.	3.3	67
3	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2022, 76, 812-821.	3.7	59
4	Does the Functional Liver Imaging Score Derived from Gadobutic Acid-enhanced MRI Predict Outcomes in Chronic Liver Disease?. <i>Radiology</i> , 2020, 294, 98-107.	7.3	51
5	Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. <i>Gut</i> , 2021, 70, 1758-1767.	12.1	51
6	Review article: therapeutic aspects of bile acid signalling in the gut-liver axis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1243-1262.	3.7	50
7	Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 194-204.	3.9	45
8	Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. <i>Hepatology</i> , 2021, 73, 1275-1289.	7.3	45
9	Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease. <i>Hepatology</i> , 2022, 76, 1563-1575.	7.3	45
10	Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease. <i>Gut</i> , 2022, 71, 402-414.	12.1	39
11	Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1362-1373.e6.	4.4	39
12	Safety of direct oral anticoagulants in patients with advanced liver disease. <i>Liver International</i> , 2021, 41, 2159-2170.	3.9	36
13	Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis. <i>United European Gastroenterology Journal</i> , 2020, 8, 321-331.	3.8	30
14	MRI-defined sarcopenia predicts mortality in patients with chronic liver disease. <i>Liver International</i> , 2020, 40, 2797-2807.	3.9	27
15	Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension. <i>Liver International</i> , 2021, 41, 799-809.	3.9	27
16	Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. <i>Journal of Hepatology</i> , 2022, 76, 1090-1099.	3.7	26
17	Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e251-e266.	4.4	25
18	Prevention of First Decompensation in Advanced Chronic Liver Disease. <i>Clinics in Liver Disease</i> , 2021, 25, 291-310.	2.1	25

#	ARTICLE	IF	CITATIONS
19	Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-to-chronic liver failure. United European Gastroenterology Journal, 2021, 9, 427-437.	3.8	22
20	Impact of <i>HSD17B13</i> rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. Liver International, 2020, 40, 393-404.	3.9	20
21	Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases. European Radiology, 2019, 29, 6600-6610.	4.5	19
22	Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies. Hepatology, 2022, 75, 610-622.	7.3	18
23	The Addition of C-reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality. Hepatology, 2021, 74, 1533-1545.	7.3	17
24	COVID-19-Related Downscaling of In-Hospital Liver Care Decreased Patient Satisfaction and Increased Liver-Related Mortality. Hepatology Communications, 2021, 5, 1660-1675.	4.3	16
25	Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease. Liver International, 2022, 42, 2501-2512.	3.9	16
26	Portal hypertensive gastropathy is associated with iron deficiency anemia. Wiener Klinische Wochenschrift, 2020, 132, 1-11.	1.9	15
27	Age-adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID-19 patients. Liver International, 2022, 42, 1297-1307.	3.9	15
28	Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. Liver International, 2020, 40, 1713-1724.	3.9	14
29	Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population. Liver International, 2020, 40, 787-796.	3.9	14
30	Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis. Hepatology International, 2020, 14, 1093-1103.	4.2	12
31	The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes. Hepatology International, 2021, 15, 1160-1173.	4.2	12
32	Recent outbreaks of severe hepatitis A virus infections in Vienna. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 335-344.	2.9	11
33	The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. Digestive and Liver Disease, 2022, 54, 500-508.	0.9	11
34	Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis. Journal of Gastroenterology, 2022, 57, 99-110.	5.1	11
35	Outcomes of an HCV elimination program targeting the Viennese MSM population. Wiener Klinische Wochenschrift, 2021, 133, 635-640.	1.9	10
36	Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19. Journal of Personalized Medicine, 2021, 11, 1264.	2.5	10

#	ARTICLE	IF	CITATIONS
37	The “Viennese epidemic” of acute HCV in the era of direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2022, 29, 385-394.	2.0	10
38	Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2164-2172.	2.8	9
39	Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension. <i>Hepatology International</i> , 2020, 14, 1083-1092.	4.2	9
40	Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLD. <i>Journal of Hepatology</i> , 2022, 77, 1005-1013.	3.7	8
41	Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites. <i>United European Gastroenterology Journal</i> , 2019, 7, 651-661.	3.8	7
42	Direct patient-physician communication via a “hepatitis” hotline facilitates treatment initiation in patients with poor adherence. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 452-460.	1.9	7
43	Long-Term Outcome of HBV-Infected Patients with Clinically Significant Portal Hypertension Achieving Viral Suppression. <i>Journal of Personalized Medicine</i> , 2022, 12, 239.	2.5	7
44	Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy. <i>Digestive and Liver Disease</i> , 2020, 52, 1473-1479.	0.9	6
45	Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 2569-2580.	4.3	6
46	Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR. <i>Journal of Personalized Medicine</i> , 2021, 11, 281.	2.5	5
47	Recent advances in the understanding and management of hepatorenal syndrome. <i>Faculty Reviews</i> , 2021, 10, 48.	3.9	5
48	Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis. <i>Platelets</i> , 2022, 33, 879-886.	2.3	5
49	Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5693-5703.	2.3	5
50	Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patients. <i>Liver International</i> , 2021, 41, 2622-2634.	3.9	3
51	Angiopoietin 2 levels decrease after HCV-cure and reflect the evolution of portal hypertension. <i>Digestive and Liver Disease</i> , 2022, 54, 1222-1229.	0.9	2
52	PS-186-Functional liver imaging score derived from gadoxetic acid-enhanced MRI predicts outcomes in patients with advanced chronic liver disease. <i>Journal of Hepatology</i> , 2019, 70, e115.	3.7	1
53	Reply to: “Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease”. <i>Journal of Hepatology</i> , 2021, 75, 234-236.	3.7	1
54	Impact of genetic variants on liver disease regression in HCV patients with advanced chronic liver disease who achieved SVR to IFN-free therapies. <i>Journal of Hepatology</i> , 2020, 73, S608-S609.	3.7	0

#	ARTICLE	IF	CITATIONS
55	Rotational thromboelastometry (rotem)-based assessment of coagulopathy in cirrhotic patients stratified by severity of portal hypertension. Journal of Hepatology, 2020, 73, S697-S698.	3.7	0
56	Differential activation of humoral compensatory mechanisms in distinct stages of portal hypertension. Journal of Hepatology, 2020, 73, S736-S737.	3.7	0
57	Impact of beta blocker therapy on systemic inflammation stratified by hepatic venous pressure gradient response. Journal of Hepatology, 2020, 73, S743-S744.	3.7	0
58	Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease. Digestive and Liver Disease, 2021, 53, 345-352.	0.9	0
59	Author's reply to "Thromboelastometry in patients with advanced chronic liver disease: a complex interplay". Hepatology International, 2021, 15, 522-524.	4.2	0
60	Adequate scattergram interpretation increases the reliability of automated polymorphonuclear (pmn) cell counts from ascitic fluid of patients with liver cirrhosis. International Journal of Laboratory Hematology, 2021, 43, O176-O180.	1.3	0
61	Reply to: "Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease". Journal of Hepatology, 2021, 74, 1000-1001.	3.7	0
62	Epidemiology of fulminant hepatitis E cases in Vienna - an informative case series. Journal of Hepatology, 2020, 73, S853-S854.	3.7	0